Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13452267 | 0.91 | MAPT (0.78) | MAPTPOLBPIK3CDPIK3CGPIK3CA | |
| SCHEMBL3151860 | 0.90 | MAPT (0.71) | MAPTPOLBPIK3CDPIK3CGPIK3CA | |
| SCHEMBL1791627 | 0.90 | MAPT (0.64) | MAPTPOLBPIK3CDPIK3CGPIK3CA | |
| SCHEMBL188285 | 0.87 | PIK3CD (0.81) | MAPTPOLBPIK3CDPIK3CGPIK3CA | |
| SCHEMBL188904 | 0.87 | MAPT (0.72) | MAPTPOLBPIK3CDPIK3CGPIK3CA | |
| SCHEMBL188837 | 0.86 | MAPT (0.74) | MAPTPOLBPIK3CDPIK3CGPIK3CA | |
| SCHEMBL12292207 | 0.85 | MAPT (0.74) | MAPTPOLBPIK3CDPIK3CGPIK3CA | |
| SCHEMBL1792393 | 0.85 | MAPT (0.72) | MAPTPOLBPIK3CDPIK3CGPIK3CA | |
| SCHEMBL188865 | 0.83 | MAPT (0.84) | MAPTPOLBPIK3CDPIK3CGPIK3CA | |
| SCHEMBL189554 | 0.83 | MAPT (0.64) | MAPTPOLBPIK3CDPIK3CGPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140128388-A1 | TARGETING AN HIV-1 NEF-HOST CELL KINASE COMPLEX | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8541415-B2 | Targeting an HIV-1 nef-host cell kinase complex | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| EP-2056829-B9 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2056829-B1 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110190241-A1 | TARGETING AN HIV-1 NEF-HOST CELL KINASE COMPLEX | UNIVERISTY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2011-08-04 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | MAPT 4580/4885POLB 1302/4885PIK3CD 2/4885 |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | MAPT 4580/4885POLB 1302/4885PIK3CD 2/4885 |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | MAPT 4606/4885POLB 1498/4885PIK3CD 2/4885 |
| US-20110190241-A1 | TARGETING AN HIV-1 NEF-HOST CELL KINASE COMPLEX | HCK, DCK, NCK1 | MAPT 1585/4885POLB 1376/4885PIK3CD 1256/4885 |
| US-20140128388-A1 | TARGETING AN HIV-1 NEF-HOST CELL KINASE COMPLEX | HCK, DCK, NCK1 | MAPT 1549/4885POLB 1437/4885PIK3CD 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.